---
title: "YD Bio Limited (YDES.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/YDES.US.md"
symbol: "YDES.US"
name: "YD Bio Limited"
industry: "Biotechnology"
---

# YD Bio Limited (YDES.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.ydesgroup.com](https://www.ydesgroup.com) |

## Company Profile

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 112 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.76% |  |
| Net Profit YoY | -10509.73% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 94.17 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 620.59M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 510360.00 |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.69% | E |
| Profit Margin | -276.58% | E |
| Gross Margin | 30.44% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 45.76% | A |
| Net Profit YoY | -10509.73% | E |
| Total Assets YoY | 2036.98% | A |
| Net Assets YoY | 28560.72% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -36.16% | D |
| OCF YoY | 45.76% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.14 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 3.99% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - YD Bio Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.69%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-276.58%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "30.44%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "45.76%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10509.73%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "2036.98%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "28560.72%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-36.16%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "45.76%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.14",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "3.99%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -439.65 | 552/604 | - | - | - |
| PB | 94.17 | 435/604 | 192.07 | 131.56 | 116.10 |
| PS (TTM) | 1215.98 | 304/604 | 2469.10 | 1691.32 | 1499.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/YDES.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/YDES.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/YDES.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.